Effectiveness and safety of ocrelizumab in a real-world setting: A single center experience from southern italy

Guerra, Tommaso; Caputo, Francesca; Bollo, Luca; Iaffaldano, Pietro; Paolicelli, Damiano; Trojano, María

doi:10.1016/j.jns.2021.117790

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Full text articles were available for 23 (44%) of the studies, while only conference abstracts were available for the remainder. Studies varied widely by geographical region; 33 reported real‐world outcomes in Europe, 7–39 seven in the United States, 40–46 two in the Middle East, 47,48 three in various geographical regions, 49–51 one in South America, 52 and six did not report the country in which the study was conducted 53–58 . The most frequently reported study populations included combined populations of RRMS, PPMS, and SPMS patients for which data were not stratified by type of MS ( n = 20).…”

Section: Resultsmentioning

confidence: 99%

“…Where reported, EDSS was assessed either by the treating neurologist or chart review. Five studies, in which patient numbers ranged from 35 to 110, performed statistical analysis of changes in absolute EDSS scores compared to baseline after receiving ocrelizumab; three reported no significant change at time points ranging from 6 months 33,56 to 1 year, 10 one reported significant improvement at 1 year, 21 and one reported progression in PPMS patients, but not RRMS patients, at a median follow‐up time of 2.09 years 19 (Table S8). One study assessed change in EDSS scores in different ethnicities exposed to ocrelizumab and found they remained stable across ethnic groups 40 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review

Montalbán¹,

Matthews

Simpson

et al. 2023

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Across its clinical development program, ocrelizumab demonstrated efficacy in improving clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed disability progression. However, as with any new treatment, it was unclear how this efficacy would translate into real‐world clinical practice. The objective of this study was to systematically collate the published real‐world clinical effectiveness data for ocrelizumab in relapsing remitting multiple sclerosis and primary progressive multiple sclerosis. A search strategy was developed in MEDLINE and Embase to identify articles reporting real‐world evidence in people with relapsing remitting multiple sclerosis or primary progressive multiple sclerosis receiving treatment with ocrelizumab. The search focused on English language articles only but was not limited by the country in which the study was conducted or the time frame of the study. Additional manual searches of relevant websites were also performed. Fifty‐two studies were identified reporting relevant evidence. Real‐world effectiveness data for ocrelizumab were consistently favorable, with reductions in relapse rate and disease progression rates similar to those reported in the OPERA I/OPERA II and ORATORIO clinical trials, including in studies with more diverse patient populations not well represented in the pivotal trials. Although direct comparisons are confounded by lack of randomization of treatments, outcomes reported suggest that ocrelizumab has a similar or greater efficacy than other therapy options. Initial real‐world effectiveness data for ocrelizumab appear favorable and consistent with results reported in clinical trials, providing clinicians with an efficacious option to treat patients with multiple sclerosis.

show abstract